MiMedx (NSDQ:MDXG) announced today that it filed a shelf registration statement on Form S-3 with the SEC.
Marietta, Ga.-based MiMedx, which develops AmnioFix, a micronized dehydrated human amnion/chorion membrane (dHACM) injection as regenerative medicine, will be allowed to sell up to $350 million in various types of securities over the next three years once the SEC declares the shelf registration effective.
Get the full story at our sister site, Drug Delivery Business News.